Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers

October 1, 2014 Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. “We wanted to study how …

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus

The HPV Cancer Vaccine: Two Doses May Be Enough

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus On Monday the 25th of August, the 29th International Papillomavirus Conference came to a close in Seattle, USA. Amongst the most hotly debated topics at the conference was lowering the number of doses of the vaccine to boost adherence rates. …

Young HIV Positive People Respond Well to HPV Vaccine

Young HIV Positive People Respond Well to HPV Vaccine

The study, Presented at the International AIDS Conference in Melbourne Last Week, Showed that the HPV Vaccine Works Just as Well for HIV-Positive Patients as it Does for HIV-Negative People Human Papillomavirus, the most common sexually transmitted infection, occurs in a variety of strains that vary in severity. People will typically become infected with HPV after they have become sexually …

HPV Vaccine, Blood clotting, VTE, USA,

HPV Vaccine Cleared Of Link To Blood Clotting

  Study shows no link between HPV vaccine and Blood Clotting The Human Papillomavirus shows no evidence of increasing Blood clot risk, according to a study by Statens Serum Institut in Copenhagen. The report features in the July 9th issue of Jama (The Journal of the American Medical Association). The report details the method in which the study was carried …

Gardasil Approved in Europe for the Prevention of Anal Cancer

The European Commission granted a new indication for Gardasil®, for the prevention of anal cancer and anal precancerous lesions caused by specific oncogenic HPV types in both females and males June 18, 2014 Sanofi Pasteur MSD announced today that the European Commission has granted marketing authorisation for the use of Gardasil for the prevention of anal precancerous lesions and anal …

Vaccine Asia Live: Current Situation of Cervical Cancer Vaccines

Levent Shih-Jen Liu, the Associate Investigator of National Health Research Institute in Taiwan, moderated the Round Table Discussion, covering the topic of cervical cancer vaccines. Human Papilloma Virus (HPV) Vaccine, a vaccine developed to prevent cervical cancer among women, has been introduced in many countries around the world, including those in Asia. Through valuable inputs from each delegate, a clear …

Vaccine Asia Live: Forging Partnerships for Improved Immunisation in Laos

“Vaccination as the most cost-efficient method to save millions of lives around the world.” To kick-start the 2nd day’s activities for World Vaccine Congress Asia 2014, we have the privilege and honour in having Dr Bounkong Syhavong, the Vice Minister of Health for Lao People’s Democratic Republic to present on the forging of partnerships for improved immunisation in Laos. For the …

Vaccine Asia Live: Recombinant Lipoimmunogen-based therapeutic HPV Vaccine

Human Papilloma Virus(HPV) is a DNA virus that can cause skin & genital warts as well as cervical and osopharyngeal cancers. In the US, there is an increasing trend in cervical cancer in women and osopharyngeal cancer in men.  To make things worse, there are no treatments available for HPV infection. Thus, HPV vaccines have become the most common mode …

Gardasil: CHMP Grants Positive Opinion for New Indication, for the Prevention of Anal Cancers and Anal Precancerous Lesions, in the European Union

European Committee for Medicinal Products for Human Use evaluated positively a new indication for the prevention of anal cancers and precancerous lesions for Gardasil April 30, 2014 Sanofi Pasteur MSD announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for Gardasil® to be used for the prevention of anal precancerous …